Home » Stocks » ADCT

ADC Therapeutics SA (ADCT)

Stock Price: $32.54 USD 0.00 (0.00%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
Market Cap 2.84B
Revenue (ttm) 2.34M
Net Income (ttm) -116.48M
Shares Out 66.87M
EPS (ttm) -2.36
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $32.54
Previous Close $32.54
Change ($) 0.00
Change (%) 0.00%
Day's Open 33.26
Day's Range 32.13 - 34.45
Day's Volume 215,926
52-Week Range 25.26 - 51.05

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 1 week ago

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly...

Business Wire - 2 weeks ago

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly...

Seeking Alpha - 4 weeks ago

Overland Pharmaceuticals will form a $117 million China JV with Allogene Therapeutics to bring allogenic CAR-T drugs to China. Harbour BioMed has out-licensed its fully human SARS-CoV-2 neutra...

Other stocks mentioned: ABBV, ALLO, BNTX, LEGN, YMAB
Business Wire - 1 month ago

LAUSANNE, Switzerland & SHANGHAI & BOSTON--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT) and Overland Pharmaceuticals, a fully integrated biopharmaceutical company backed by Hillhouse Capit...

Business Wire - 1 month ago

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly...

Business Wire - 1 month ago

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly...

Business Wire - 1 month ago

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highl...

Seeking Alpha - 2 months ago

ADC Therapeutics' (ADCT) CEO Chris Martin on Q3 2020 Results - Earnings Call Transcript

Business Wire - 2 months ago

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highl...

Zacks Investment Research - 2 months ago

ADC Therapeutics (ADCT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Business Wire - 2 months ago

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highl...

Business Wire - 2 months ago

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highl...

Business Wire - 2 months ago

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly...

Business Wire - 2 months ago

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highl...

GlobeNewsWire - 2 months ago

Media Release Copenhagen, Denmark and Lausanne, Switzerland, October 30, 2020

Other stocks mentioned: GMAB
Business Wire - 3 months ago

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highl...

Business Wire - 3 months ago

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly...

Business Wire - 3 months ago

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly...

Business Wire - 3 months ago

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highl...

Business Wire - 4 months ago

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highl...

Business Wire - 4 months ago

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highl...

Business Wire - 4 months ago

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), today gave notice that Morgan Stanley & Co. LLC and BofA Securities, Inc.

Seeking Alpha - 5 months ago

ADC Therapeutics SA (ADCT) CEO Christopher Martin on Q2 2020 Results - Earnings Call Transcript

Business Wire - 5 months ago

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highl...

Business Wire - 5 months ago

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highl...

Business Wire - 5 months ago

AMSTERDAM--(BUSINESS WIRE)--Synaffix B.V., a biotechnology company focused on enabling antibody-drug conjugates (ADCs) with superior therapeutic index based on its proprietary ADC technology p...

Business Wire - 6 months ago

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly...

Business Wire - 6 months ago

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a clinical-stage oncology-focused biotechnology company leading the development and commercialization of next-generatio...

PRNewsWire - 6 months ago

VIRGINIA BEACH, Va., June 30, 2020 /PRNewswire/ -- New Ventures Funds, a venture fund targeting investments in companies across healthcare and life sciences, is pleased to announce the IPO of ...

Market Watch - 8 months ago

ADC Therapeutics S.A. ADCT, +59.10% shares rocketed 56% Friday in their trading debut, after the Swiss biotech's initial public offering priced above its proposed price range and underwriters ...

About ADCT

ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its lead product candidates are ADCT-402, an ADC that is in a Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma; and ADCT-301, an ADC that is in a pivotal Phase II clinical trial for the treatment of relapsed or refractory Hodgkin lymphoma, non-Hodgkin lymphoma, and solid tumors. The company also develops clin... [Read more...]

Industry
Biotechnology
IPO Date
May 15, 2020
CEO
Dr. Christopher J. Martin
Stock Exchange
NYSE
Ticker Symbol
ADCT
Full Company Profile

Financial Performance

In 2019, ADCT's revenue was $2.34 million, an increase of 105.26% compared to the previous year's $1.14 million. Losses were -$116.48 million, -5.37% less than in 2018.

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for ADCT is 48.75, which is an increase of 49.82% from the latest price.

Price Target
$48.75
(49.82% upside)